Mr. Movahhed’s extensive background in clinical operations will bring great value to our pharmaceutical clients who are conducting clinical trials in a variety of therapeutic areas including oncology, neurology, and cardiology.
Rochelle, Virginia (PRWEB) August 20, 2020
NDA Partners Chairman Carl Peck, MD, announced today that Hassan Movahhed, a Clinical Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection readiness, and clinical investigator and CRO management, has joined the firm as an Expert Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, and anti-infective clinical trials and has prepared for pre-approval regulatory inspections.
Prior to joining NDA Partners, Mr. Movahhed served in Vice President or Senior Vice President roles at several companies including Exelixis, Forty-Seven, Inc., United Therapeutics, Elan, Geron, and Threshold Pharmaceuticals. He was formerly Senior Director and Head of US Development Operations and Clinical Affairs at Amgen and Senior Director of Clinical Operations at ICOS. In his early career, he served in roles of increasing responsibility at Bristol-Myers Squibb in infectious disease clinical research and drug pharmacokinetics and metabolism research.
“Mr. Movahhed’s extensive background in clinical operations will bring great value to our pharmaceutical clients who are conducting clinical trials in a variety of therapeutic areas including oncology, neurology, and cardiology. We are pleased to welcome him to NDA Partners,” said Dr. Peck.
Mr. Movahhed earned a master’s degree in biology and bachelor’s degree in zoology from the University of Michigan.
About NDA Partners
NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.
Earle Martin, Chief Executive Officer